Investment
Interstitial NS has considerable expertise which can be resourced and utilised to add maximum value to projects and products in the areas of therapeutics, drug delivery and vaccines.
Partnering opportunities
 Interstitial NS is seeking development partners for its exciting portfolio of bioengineering, nanoformulation and delivery technologies with the intent of rapidly moving all initial applications for each platform through to readiness for clinical trials. This product pathway involves further development of the underlying technology for optimisation for the delivery of the specific biologicals/pharmaceuticals and vaccines. Interstitial NS is seeking partners with:
- Proprietary position and expertise in drug delivery
- Access to drug formulations
- Financial and management resources
Interested parties are encouraged to contact us to discuss the opportunities available. Interstitial NS will consider licensing its technologies for applications in specific fields or territories, and furthermore will also undertake the demonstration and optimisation of a partner’s proprietary therapeutic or diagnostic reagents.
In-Licensing opportunities
Interstitial NS is seeking companies that will out-license products, in particular protein based and nanotechnology enabled materials that are in the development and late pre-clinical phase.
Interstitial NS provides revenue opportunities for pharmaceutical manufacturers by providing access to broader and alternate drug delivery markets through the novel delivery systems, extending patent life on reagents.
Investment opportunities
 Interstitial NS – the vehicle for commercialising the institutional and NanoVic funding outcomes – encourages potential investors to consider the complete package of complementary technologies for investment. However we also recognise specialist focus of some investors and under some circumstances be willing to discuss individual technologies and applications.
The business model adopted invokes a 2 year development program to take the Interstitial NS’ activities to be clinical trial and second round of funding ready.
Call us on +61 3 9905 8696 or contact us for more information.
|
